This is a competitive renewal application of a project initially designed to define mechanisms of cardiac myocyte dysfunction that leads to heart failure, a significant health problem in the US. Work in previous funding cycles has shown that cardiac diseases cause abnormalities in intracellular Calcium regulation and myocyte contractility. These abnormalities lead to cell death, and reduction in the number of functional cardiac myocytes. The major goal of the proposed research is to test/develop novel cell-based approaches to repair the heart after myocardial infarction (MI). The idea is that cardiac structura and functional decline after MI can be reduced or corrected using cell therapy.
The Aims are to 1) Determine if/how enhancing Cn43 expression in cardiac (CSC) or compact bone derived stem cells (CBSCs) enhances their survival, engraftment and differentiation into new cardiac tissue when injected into the infarct border zone after MI~ thus increasing their capacity to improve post-MI cardiac structure and function~ and 2) Determine the role of ?1G T-type Ca2+ channels (TTCCs) in the generation of new myocytes derived from either CSCs or proliferative cardiac myocytes after MI. Our recent work shows that CBSCs are a novel cell with the capacity to improve cardiac function in mouse MI models. The new work will define the mechanisms (differentiation into new cardiac tissue and/or enhancing endogenous repair of the native heart) of CBSC-mediated repair. A novel lineage tracing approach will be used to unambiguously examine these issues. These studies will also determine if enhancing Cn43 coupling of CBSCs and cardiac myocytes enhances stem cell survival and differentiation into new cardiac myocytes. Our recent work also shows that TTCCs regulate stem cell proliferation and commitment to the cardiac lineage.
In Aim 2 studies we will determine if modulation of TTCCs in cKit+ CSCs alters the ability of these cells to form new cardiac myocytes after MI. Finally we will perform proof of concept experiments without most efficacious cells (defined in mice) in a pig MI model, to document that the strategies being developed have the potential to translate to patients with ischemic heart disease.

Public Health Relevance

Myocardial infarction (MI) is a major health problem in the US. MI leads to poor performance of the heart because of the death of cardiac muscle cells. Our project will explore novel cells that appear to have an enhanced ability to repair the heart that has been injured by MI. The science proposed culminates in a proof of concept test of the most promising cell type in a large animal model. These studies could lead to early stage clinical trial and eventually in improved MI therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL033921-31
Application #
8760748
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Krull, Holly
Project Start
1985-06-01
Project End
2018-04-30
Budget Start
2014-08-01
Budget End
2015-04-30
Support Year
31
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Temple University
Department
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Harper, Shavonn C; Brack, Andrew; MacDonnell, Scott et al. (2016) Is Growth Differentiation Factor 11 a Realistic Therapeutic for Aging-Dependent Muscle Defects? Circ Res 118:1143-50; discussion 1150
Wallner, Markus; Duran, Jason M; Mohsin, Sadia et al. (2016) Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration. Circ Res 119:865-79
Woitek, Felix; Zentilin, Lorena; Hoffman, Nicholas E et al. (2015) Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy. J Am Coll Cardiol 66:139-53
Garikipati, Venkata Naga Srikanth; Krishnamurthy, Prasanna; Verma, Suresh Kumar et al. (2015) Negative Regulation of miR-375 by Interleukin-10 Enhances Bone Marrow-Derived Progenitor Cell-Mediated Myocardial Repair and Function After Myocardial Infarction. Stem Cells 33:3519-29
Makarewich, Catherine A; Troupes, Constantine D; Schumacher, Sarah M et al. (2015) Comparative effects of urocortins and stresscopin on cardiac myocyte contractility. J Mol Cell Cardiol 86:179-86
Smith, Shavonn C; Zhang, Xiaoxiao; Zhang, Xiaoying et al. (2015) GDF11 does not rescue aging-related pathological hypertrophy. Circ Res 117:926-32
Leipsic, Jonathon A (2015) President's Page. J Cardiovasc Comput Tomogr 9:604-5
Sallam, Karim; Li, Yingxin; Sager, Philip T et al. (2015) Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res 116:1989-2004
Hullmann, Jonathan E; Grisanti, Laurel A; Makarewich, Catherine A et al. (2014) GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ Res 115:976-85
Grisanti, Laurel A; Talarico, Jennifer A; Carter, Rhonda L et al. (2014) β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. J Mol Cell Cardiol 72:39-51

Showing the most recent 10 out of 75 publications